News

ReCode Therapeutics has raised $50 million in extended series B financing, which the company plans to use to help develop RCT2100, its experimental treatment for cystic fibrosis (CF). “We are delighted with the continued high level of interest in our novel approach to the targeted delivery of genetic…

Inogen has acquired Physio-Assist, including Simeox, a technology for airway clearance and mucus management in people with cystic fibrosis (CF). The company will continue marketing Simeox in Europe, Asia, and the Middle East, while pursuing regulatory clearance in the U.S. This acquisition will expand Inogen’s portfolio of…

The public is invited to help select this year’s two AbbVie Cystic Fibrosis Scholarship “Thriving Students,” who will be awarded an additional $22,000 in support of their higher education. As it has done for decades, AbbVie gave scholarships worth $3,000 to 40 undergraduate and graduate students living…

Researchers from Vertex Pharmaceuticals have been awarded the 2024 Breakthrough Prize in Life Sciences for their work developing CFTR modulator therapies for people with cystic fibrosis (CF). Breakthrough Awards, known as the “Oscars of Science,” are granted to scientists who have made important discoveries in life sciences, fundamental…

A European Medicines Agency (EMA) committee has recommended expanding Kaftrio’s (ivacaftor, tezacaftor, and elexacaftor) label to be used in combination with Kalydeco (ivacaftor) in children with cystic fibrosis (CF) ages 2 to 5 who have at least one F508del mutation in the CFTR gene. The CFTR modulator…

Infections with Staphylococcus aureus small colony variants, known as SCVs, are highly prevalent in people with cystic fibrosis (CF) — and linked to the previous use of the broad-spectrum antibiotic trimethoprim sulfamethoxazole, a systematic literature review has found. SCVs are slow-growing bacteria that are associated with higher rates of chronic…

BX004, a virus-based cocktail designed to treat Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), can reduce the number of bacteria in the lungs with no signs of resistance to treatment over time, a study has found. Findings from the first part of a small Phase 1b/2a…

A year of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly reduces recurrent nose and sinus inflammation — called chronic rhinosinusitis, or CRS — in people with cystic fibrosis (CF), though most patients still exhibit signs of severe sinus disease. These are the findings of a new U.S. study that, similar to…

A type of bacteria called Achromobacter, which can cause problematic lung infections in people with cystic fibrosis (CF), uses a molecular weapon — one known as a type 3 secretion system — to induce a powerful inflammatory response during infections, a new study found. “These bacteria resist the action…

LasB, an enzyme that promotes Pseudomonas aeruginosa infections in the lungs of people with cystic fibrosis (CF), is significantly more active in the early stages of infection with the bacteria, known more simply as P. aeruginosa, a study revealed. These findings suggest that therapies targeting LasB may be…